JAK Plus Excimer Laser Hits 85% in Pediatric Vitiligo Trial

A multicenter, prospective randomized controlled trial published in the [Journal of the American Academy of Dermatology](https://doi.org/10.1016/j.jaad.2026.02.096){rel="nofollow noopener" target="_blank"} reports that oral JAK inhibitors combined with 308-nm excimer laser produced an 85.5% overall response rate in 188 children with progressive vitiligo, versus 53.8% with topical tacrolimus plus the same laser protocol. Conducted across five academic dermatology centers in China over 48 weeks, it is the first prospective RCT to test a JAK-plus-phototherapy regimen in a strictly pediatric vitiligo population. The publication was amplified on May 18, 2026 by STRATA Skin Sciences, which manufactures the [XTRAC 308-nm excimer laser](https://www.globenewswire.com/news-release/2026/05/18/3296628/23161/en/New-Peer-Reviewed-Publication-Confirms-Unprecedented-Response-Rates-for-STRATA-s-Excimer-Laser-Combined-with-JAK-Inhibitors-in-Pediatric-Vitiligo.html){rel="nofollow noopener" target="_blank"} used in both arms. ## Why Pediatric Vitiligo Has Been the Most Therapeutically Neglected Subgroup Vitiligo is an autoimmune condition in which CD8-positive T cells destroy melanocytes, producing well-demarcated patches of depigmented skin. Adult treatment has advanced quickly. Topical ruxolitinib cream received FDA approval in 2022, and AbbVie has filed for an oral upadacitinib indication in non-segmental vitiligo, a story we covered when the systemic agent met its [Phase 3 co-primary endpoints earlier this year](/science/upadacitinib-vitiligo-first-systemic-treatment/). Children have been left behind in that pipeline. Topical tacrolimus and narrowband UVB have been the most common interventions for younger patients, both with modest and variable repigmentation. Chang et al. randomized 188 patients aged 2–18 with progressive disease to either oral JAK inhibitor (baricitinib or tofacitinib) plus 308-nm excimer twice weekly, or topical tacrolimus plus the same excimer protocol, for 48 weeks. The mechanism behind the combination is two-pronged: JAK inhibitors shut down the IFN-γ/JAK-STAT1 signaling cascade that drives melanocyte autoimmunity, while the 308-nm excimer laser induces targeted apoptosis of pathogenic T cells at the dermo-epidermal junction and stimulates melanocyte migration from the hair follicle reservoir into lesional skin. One arm addresses the immune signal; the other addresses the repigmentation gap. ## How Large Was the Response in the Combination Arm? The combination achieved 85.5% overall response versus 53.8% in the control (P<.001), with the largest gains on the face and neck. Facial and neck lesions reached a 97.3% response rate with 64.9% scored as "significantly effective," compared with 59.5% in the tacrolimus arm. Thirty-three lesions achieved greater than 95% repigmentation by week 48 in the combination arm, versus three in the control. Mixed-effects modeling confirmed a 21.7% higher repigmentation rate for the combination (β = 0.217, 95% CI 0.204–0.230, P<.001). Quality-of-life gains, measured by the Children's Dermatology Life Quality Index, reached statistical significance by week 48 (P<.001). The face and neck numbers carry the most clinical weight. Pediatric vitiligo's psychosocial burden is concentrated in visible areas, and facial response has historically been the hardest to predict. Safety data were uneventful across 48 weeks: all adverse events were mild to moderate and fully resolved, with no cases of tuberculosis or hepatitis B/C in either arm. The pediatric tolerability signal matters because the systemic-JAK class carries a boxed warning in adults for serious infections, malignancies, and thrombotic events. ## What This Means for Vitiligo Care Beyond the Trial Combination phototherapy plus systemic immunomodulation has been the implicit direction of vitiligo care for several years, but the pediatric evidence base has lagged the adult literature. Chang et al. close part of that gap. The data argue for moving pediatric treatment selection toward multi-mechanism regimens earlier in the disease course, particularly where progressive disease narrows the window for melanocyte rescue. The 308-nm excimer laser's role as a phototherapy backbone is also reinforced: the 21.7% delta represents the JAK inhibitor's added value on top of an already-active phototherapy regimen, not its standalone effect. Clinicians weighing access to targeted phototherapy versus broad-area narrowband UVB now have additional data favoring the targeted modality in combination protocols. The reimbursement environment is shifting alongside the science. The American Medical Association's CPT Editorial Panel approved updates to codes 96920–96922, effective January 1, 2027, that expand reimbursement eligibility for excimer laser treatment to all inflammatory and autoimmune skin conditions, including vitiligo, atopic dermatitis, and [alopecia areata](/science/rinvoq-alopecia-areata-fda-submission-2026/). The change broadens coverage for families whose plans previously limited reimbursement to psoriasis. The trial does not settle the durability question. Forty-eight weeks captures the active treatment phase but not the sustained-response window after stepdown, the long-standing concern with any vitiligo intervention. The investigators flag durability and relapse as the natural next research questions. ## When Will Pediatric Combination Protocols Reach Routine Practice? Excimer phototherapy is available in most large academic dermatology departments in the United States, and both baricitinib and tofacitinib are FDA-approved in pediatric populations for other indications, with off-label vitiligo prescribing already in use at experienced centers. The barriers to adoption are practical: insurance coverage for excimer in non-psoriasis pediatric indications, monitoring infrastructure for systemic JAK use in children, and clinician comfort with the combined regimen. The 2027 CPT update resolves part of the insurance problem; longer-term safety follow-up and trials in more diverse populations will resolve the rest.